Kurv Tesla(TSLA)收益溢價策略主動型ETF TSLP 深 滬
已收盤 05-08 16:00:00 美东时间
19.78
+0.680
+3.56%
華盛通- 最 高19.945
- 今 開19.41
- 成交量 2.45万股
- 最 低 19.33
- 昨 收 19.10
- 總市值 2274.70万
- 52周最高 24.169
- 市盈率 靜 --
- 換手率 2.13%
- 52周最低 12.50
- 委 比 -88.68%
- 總股本 115.00万
- 歷史最高 23.3895
- 量 比 0.88
- 振 幅 3.22%
- 歷史最低 1.3523
- 每 手 1
- 風險率 2.61%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Keymed Biosciences publishes 2025 annual report
Keymed Biosciences publishes 2025 annual report Keymed Biosciences annual report for year ended Dec. 31, 2025 flagged shift toward dual engine of R&D, commercialization, led by full commercial launch of IL-4Rα antibody Kangyueda. Kangyueda secured NRDL listing in Dec. 2025 for three indications, cov
04-29 17:00
Aclaris Therapeutics to Reveal Clinical Update On Key Biologic And Oral Inhibitor Programs on April 28, 2026
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide the full results
04-28 04:50
Upstream Bio Announces Presentation Of New Data From Phase 2 VIBRANT Trial At American Thoracic Society Meeting On May 18
The presentations feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only known antagonist to the thymic stromal lymphopoietin (TSLP) receptor currently in clinical development, in chronic
04-17 19:07
Generate Biomedicines publishes corporate presentation on programmable biology drug design platform
Generate Biomedicines publishes corporate presentation on programmable biology drug design platform Generate Biomedicines outlined strategy to use generative biology and scaled lab automation to lower drug-discovery time to proof of concept to 3-5 years from 6-8 years. Company also projected cost to
04-08 19:07
“芯片搬运工”一季度业绩暴涨，净利同比最高预增超87倍！ | 盘后公告精选
存储芯片“批发商”披露一季度业绩预告，千亿锂矿巨头再斥巨资扩产，七连板医药股又提示交易风险......
04-07 21:03
From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker
Sanofi reports positive Phase 2 data for lunsekimig in asthma and nasal polyps, while atopic dermatitis study misses main goal.
04-07 19:02
Harbour BioMed publishes Phase I results for TSLP antibody HBM9378 in 50 healthy adults
Harbour BioMed publishes Phase I results for TSLP antibody HBM9378 in 50 healthy adults Harbour BioMed reported online publication of first-in-human Phase I results from a randomized, double-blind, placebo-controlled single-ascending-dose trial of HBM9378 (SKB378/WIN378), a TSLP-targeting monoclonal
03-23 11:15
Pfizer's Phase 2 Study Investigating Tilrekimig In Adults With Moderate To Severe Atopic Dermatitis Met Its Primary Efficacy Endpoint
Study met primary endpoint, demonstrating statistically significant increase in the percentage of participants achieving EASI-75 at Week 16 across all doses tested, compared to placeboTilrekimig (PF-07275315) was
03-09 18:47
Aclaris posts Q4 net loss of USD 19.8 million (-79.5%)
Aclaris posts Q4 net loss of USD 19.8 million (-79.5%) Aclaris reported a net loss of USD 19.8 million in Q4 2025 and USD 64.9 million for FY 2025. Total revenue was USD 1.3 million in Q4 2025 and USD 7.8 million in FY 2025. R&D expenses rose to USD 16.6 million in Q4 2025 and USD 52.6 million in FY
02-26 19:58
